312 related articles for article (PubMed ID: 12881518)
1. Suppression of NF-kappa B survival signaling by nitrosylcobalamin sensitizes neoplasms to the anti-tumor effects of Apo2L/TRAIL.
Chawla-Sarkar M; Bauer JA; Lupica JA; Morrison BH; Tang Z; Oates RK; Almasan A; DiDonato JA; Borden EC; Lindner DJ
J Biol Chem; 2003 Oct; 278(41):39461-9. PubMed ID: 12881518
[TBL] [Abstract][Full Text] [Related]
2. Nitric Oxide Inhibits NF-κB-mediated Survival Signaling: Possible Role in Overcoming TRAIL Resistance.
Bauer JA; Lupica JA; Didonato JA; Lindner DJ
Anticancer Res; 2020 Dec; 40(12):6751-6763. PubMed ID: 33288568
[TBL] [Abstract][Full Text] [Related]
3. Nitrosylcobalamin potentiates the anti-neoplastic effects of chemotherapeutic agents via suppression of survival signaling.
Bauer JA; Lupica JA; Szugye H; Morrison BH; Haney RM; Masci RK; Lee RM; Didonato JA; Lindner DJ
PLoS One; 2007 Dec; 2(12):e1313. PubMed ID: 18074035
[TBL] [Abstract][Full Text] [Related]
4. IFN-beta pretreatment sensitizes human melanoma cells to TRAIL/Apo2 ligand-induced apoptosis.
Chawla-Sarkar M; Leaman DW; Jacobs BS; Borden EC
J Immunol; 2002 Jul; 169(2):847-55. PubMed ID: 12097388
[TBL] [Abstract][Full Text] [Related]
5. Sensitization of tumor cells to Apo2 ligand/TRAIL-induced apoptosis by inhibition of casein kinase II.
Ravi R; Bedi A
Cancer Res; 2002 Aug; 62(15):4180-5. PubMed ID: 12154014
[TBL] [Abstract][Full Text] [Related]
6. TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications.
Mitsiades CS; Treon SP; Mitsiades N; Shima Y; Richardson P; Schlossman R; Hideshima T; Anderson KC
Blood; 2001 Aug; 98(3):795-804. PubMed ID: 11468181
[TBL] [Abstract][Full Text] [Related]
7. Requirement of BAX for TRAIL/Apo2L-induced apoptosis of colorectal cancers: synergism with sulindac-mediated inhibition of Bcl-x(L).
Ravi R; Bedi A
Cancer Res; 2002 Mar; 62(6):1583-7. PubMed ID: 11912124
[TBL] [Abstract][Full Text] [Related]
8. NF-kappaB-independent actions of sulfasalazine dissociate the CD95L- and Apo2L/TRAIL-dependent death signaling pathways in human malignant glioma cells.
Hermisson M; Weller M
Cell Death Differ; 2003 Sep; 10(9):1078-89. PubMed ID: 12934082
[TBL] [Abstract][Full Text] [Related]
9. Adriamycin sensitizes the adriamycin-resistant 8226/Dox40 human multiple myeloma cells to Apo2L/tumor necrosis factor-related apoptosis-inducing ligand-mediated (TRAIL) apoptosis.
Jazirehi AR; Ng CP; Gan XH; Schiller G; Bonavida B
Clin Cancer Res; 2001 Dec; 7(12):3874-83. PubMed ID: 11751478
[TBL] [Abstract][Full Text] [Related]
10. Nitrosylcobalamin promotes cell death via S nitrosylation of Apo2L/TRAIL receptor DR4.
Tang Z; Bauer JA; Morrison B; Lindner DJ
Mol Cell Biol; 2006 Aug; 26(15):5588-94. PubMed ID: 16847314
[TBL] [Abstract][Full Text] [Related]
11. Molecular determinants of kinase pathway activation by Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand.
Varfolomeev E; Maecker H; Sharp D; Lawrence D; Renz M; Vucic D; Ashkenazi A
J Biol Chem; 2005 Dec; 280(49):40599-608. PubMed ID: 16227629
[TBL] [Abstract][Full Text] [Related]
12. Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications.
Mitsiades CS; Mitsiades N; Poulaki V; Schlossman R; Akiyama M; Chauhan D; Hideshima T; Treon SP; Munshi NC; Richardson PG; Anderson KC
Oncogene; 2002 Aug; 21(37):5673-83. PubMed ID: 12173037
[TBL] [Abstract][Full Text] [Related]
13. Curcumin sensitizes prostate cancer cells to tumor necrosis factor-related apoptosis-inducing ligand/Apo2L by inhibiting nuclear factor-kappaB through suppression of IkappaBalpha phosphorylation.
Deeb D; Jiang H; Gao X; Hafner MS; Wong H; Divine G; Chapman RA; Dulchavsky SA; Gautam SC
Mol Cancer Ther; 2004 Jul; 3(7):803-12. PubMed ID: 15252141
[TBL] [Abstract][Full Text] [Related]
14. Concepts in the use of TRAIL/Apo2L: an emerging biotherapy for myeloma and other neoplasias.
Mitsiades N; Mitsiades CS; Poulaki V; Anderson KC; Treon SP
Expert Opin Investig Drugs; 2001 Aug; 10(8):1521-30. PubMed ID: 11772267
[TBL] [Abstract][Full Text] [Related]
15. Enhancement of Apo2L/TRAIL (tumor necrosis factor-related apoptosis-inducing ligand)-induced apoptosis in non-small cell lung cancer cell lines by chemotherapeutic agents without correlation to the expression level of cellular protease caspase-8 inhibitory protein.
Frese S; Brunner T; Gugger M; Uduehi A; Schmid RA
J Thorac Cardiovasc Surg; 2002 Jan; 123(1):168-74. PubMed ID: 11782771
[TBL] [Abstract][Full Text] [Related]
16. Pathways involved in proliferating, senescent and immortalized keratinocyte cell death mediated by two different TRAIL preparations.
Qin JZ; Bacon PE; Chaturvedi V; Bonish B; Nickoloff BJ
Exp Dermatol; 2002 Dec; 11(6):573-83. PubMed ID: 12473065
[TBL] [Abstract][Full Text] [Related]
17. Synergy is achieved by complementation with Apo2L/TRAIL and actinomycin D in Apo2L/TRAIL-mediated apoptosis of prostate cancer cells: role of XIAP in resistance.
Ng CP; Zisman A; Bonavida B
Prostate; 2002 Dec; 53(4):286-99. PubMed ID: 12430140
[TBL] [Abstract][Full Text] [Related]
18. X-linked inhibitor of apoptosis (XIAP) blocks Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis of prostate cancer cells in the presence of mitochondrial activation: sensitization by overexpression of second mitochondria-derived activator of caspase/direct IAP-binding protein with low pl (Smac/DIABLO).
Ng CP; Bonavida B
Mol Cancer Ther; 2002 Oct; 1(12):1051-8. PubMed ID: 12481428
[TBL] [Abstract][Full Text] [Related]
19. Caspase cleavage product lacking amino-terminus of IkappaBalpha sensitizes resistant cells to TNF-alpha and TRAIL-induced apoptosis.
Kim KW; Kim BJ; Chung CW; Jo DG; Kim IK; Song YH; Kwon YK; Woo HN; Jung YK
J Cell Biochem; 2002; 85(2):334-45. PubMed ID: 11948689
[TBL] [Abstract][Full Text] [Related]
20. Doxorubicin increases the effectiveness of Apo2L/TRAIL for tumor growth inhibition of prostate cancer xenografts.
El-Zawahry A; McKillop J; Voelkel-Johnson C
BMC Cancer; 2005 Jan; 5():2. PubMed ID: 15638938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
